Avalo Therapeutics (AVTX) Accounts Payables (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Accounts Payables data on file, last reported at $356000.0 in Q1 2026.

• Quarterly Accounts Payables fell 47.72% year-over-year to $356000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356000.0 (down 47.72% YoY) and the FY2025 annual result came in at $137000.0, down 51.59% from the prior year.
• Accounts Payables grew to $356000.0 in Q1 2026, from $137000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.6 million in Q1 2023 to a low of $137000.0 in Q4 2025.
• A 5-year average of $1.5 million and a median of $789000.0 in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables tumbled 84.52% — and 2025, when it jumped 261.77%.
• Tracing AVTX's Accounts Payables over 5 years: stood at $2.9 million in 2022, then tumbled by 84.52% to $446000.0 in 2023, then slumped by 36.55% to $283000.0 in 2024, then slumped by 51.59% to $137000.0 in 2025, then jumped by 159.85% to $356000.0 in 2026.
• The last three Accounts Payables figures came in at $356000.0 (Q1 2026), $137000.0 (Q4 2025), and $474000.0 (Q3 2025), per Business Quant data.